Haemonetics (NYSE:HAE) Cut to “Hold” at Wall Street Zen

Wall Street Zen downgraded shares of Haemonetics (NYSE:HAE) from a buy rating to a hold rating in a report issued on Sunday.

A number of other research analysts also recently commented on the stock. BTIG Research reaffirmed a “buy” rating and issued a $88.00 price target on shares of Haemonetics in a report on Friday, November 21st. Barrington Research upped their price objective on Haemonetics from $86.00 to $90.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Citigroup dropped their target price on Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, October 7th. Weiss Ratings reissued a “hold (c-)” rating on shares of Haemonetics in a research report on Monday, December 8th. Finally, JPMorgan Chase & Co. raised their price target on Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a research report on Friday, December 12th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $82.10.

Haemonetics Stock Performance

NYSE:HAE opened at $80.93 on Friday. The company has a market cap of $3.79 billion, a price-to-earnings ratio of 23.66, a PEG ratio of 1.52 and a beta of 0.30. Haemonetics has a 1 year low of $47.31 and a 1 year high of $87.32. The stock’s 50 day simple moving average is $66.63 and its two-hundred day simple moving average is $64.58. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.15. The company had revenue of $327.32 million for the quarter, compared to analysts’ expectations of $311.61 million. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. Haemonetics’s quarterly revenue was down 5.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, equities analysts anticipate that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Institutional Trading of Haemonetics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. increased its stake in Haemonetics by 0.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 556,027 shares of the medical instruments supplier’s stock worth $35,336,000 after buying an additional 4,834 shares during the period. Invesco Ltd. grew its stake in Haemonetics by 10.1% in the 1st quarter. Invesco Ltd. now owns 105,645 shares of the medical instruments supplier’s stock worth $6,714,000 after acquiring an additional 9,654 shares in the last quarter. Nuveen LLC bought a new position in Haemonetics in the 1st quarter worth about $10,340,000. Fox Run Management L.L.C. purchased a new position in shares of Haemonetics during the first quarter worth approximately $711,000. Finally, Raymond James Financial Inc. raised its stake in shares of Haemonetics by 60.6% during the first quarter. Raymond James Financial Inc. now owns 390,856 shares of the medical instruments supplier’s stock valued at $24,839,000 after acquiring an additional 147,492 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.